By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Group I antiarrhythmics > Quin-g > Quinidine Dosage
Group I antiarrhythmics
https://themeditary.com/dosage-information/quinidine-dosage-3841.html

Quinidine Dosage

Drug Detail:Quin-g (Quinidine (oral/injection) [ kwih-nih-deen ])

Drug Class: Group I antiarrhythmics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Arrhythmias

Tablet (sulfate):100 to 600 mg/dose orally every 4 to 6 hours; begin at 200 mg/dose and titrate to desired effect (maximum daily dose: 3 to 4 g).
Extended Release: 324 to 648 mg (gluconate) orally every 8 to 12 hours or 300 to 600 mg (sulfate) orally every 8 to 12 hours.
IV: 800 mg of quinidine gluconate diluted to 50 mL and given at a rate not to exceed 1 mL/min.

Usual Adult Dose for Malaria

Test Dose: 200 mg quinidine sulfate tablet or quinidine gluconate IM injection to determine possibility of idiosyncratic reaction.

Dosage Regimen 1:
Loading dose: 24 mg/kg of quinidine gluconate diluted in 250 mL infused over 4 hours.
Maintenance dose: Start in 24 hours, 12 mg/kg of quinidine gluconate diluted in 250 mL over 4 hours every 8 hours for 7 days or until oral therapy.

Dosage Regimen 2:
Loading dose: 10 mg/kg of quinidine gluconate diluted in 250 mL over 1 to 2 hours.
Maintenance dose: 0.02 mg/kg/min of quinidine gluconate for up to 72 hours.

Omit quinidine loading dose if patient received more than 40 mg/kg of quinine in preceding 48 hours or mefloquine within preceding 12 hours.

Change to oral quinine once parasite density is less than 1% and patient can receive oral medication to complete treatment course; total duration of treatment (quinidine/quinine): 3 days in Africa or South America; 7 days in Southeast Asia; use in combination with doxycycline, tetracycline, or clindamycin.

Usual Pediatric Dose for Malaria

Test Dose: 200 mg quinidine sulfate tablet or quinidine gluconate IM injection to determine possibility of idiosyncratic reaction.

Dosage Regimen 1:
Loading dose: 24 mg/kg of quinidine gluconate diluted in 250 mL infused over 4 hours.
Maintenance dose: Start in 24 hours, 12 mg/kg of quinidine gluconate diluted in 250 mL over 4 hours every 8 hours for 7 days or until oral therapy.

Dosage Regimen 2:
Loading dose: 10 mg/kg of quinidine gluconate diluted in 250 mL over 1 to 2 hours.
Maintenance dose: 0.02 mg/kg/min of quinidine gluconate for up to 72 hours.

Omit quinidine loading dose if patient received more than 40 mg/kg of quinine in preceding 48 hours or mefloquine within preceding 12 hours.

Change to oral quinine once parasite density is less than 1% and patient can receive oral medication to complete treatment course; total duration of treatment (quinidine/quinine): 3 days in Africa or South America; 7 days in Southeast Asia; use in combination with doxycycline, tetracycline, or clindamycin.

Renal Dose Adjustments

If creatinine clearance is less than 10 mL/minute, administer 75% of normal dose.

Liver Dose Adjustments

Reduce maintenance dose by 50% and monitor serum levels closely.

Precautions

US BOXED WARNING:

  • MORTALITY: Active antiarrhythmic therapy has resulted in increased mortality. Risk of active therapy may be greatest in patients with structural heart disease. In a meta-analysis of trials that used this drug to prevent or defer recurrence of atrial flutter/fibrillation, mortality associated with this drug was more than 3 times higher than mortality associated with placebo. In another meta-analysis of trials involving patients with various non-life-threatening ventricular arrhythmias, mortality associated with this drug was consistently greater than mortality associated with any of a variety of alternative antiarrhythmics.

Patients should be monitored on telemetry when first started on quinidine and for 48 hours after steady state. The QTc interval should be checked on a regular basis and with any increase in dose. When using quinidine in patients with atrial flutter/fibrillation, the desired pharmacologic reversion to sinus rhythm may (rarely) be preceded by a slowing of the atrial rate with a consequent increase in the rate of beats conducted to the ventricles. This hazard may be decreased if partial AV block is achieved prior to initiation of quinidine therapy, using conduction reducing drugs such as digitalis, verapamil, diltiazem, or beta-receptor blocking agents.

Dialysis

Quinidine is slightly hemodialyzable (5%-20%). A 200 mg supplemental dose post hemodialysis dose is recommended. Quinidine is not removed by peritoneal dialysis.

Other Comments

Dosages exceeding 648 mg (gluconate) every 8 hours or 600 mg (sulfate) every 6 hours are not recommended except for patients with relatively large actual body weight.

Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by